Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.

Casado E, Garcia VM, Sánchez JJ, Gómez Del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, López RA, García-Cabezas MÁ, Burgos E, de Castro J, Belda-Iniesta C, López-Gómez M, Gómez-Raposo C, Zambrana F, Sereno M, Fernández-Martos C, Vázquez P, Lacal JC, González-Barón M, Cejas P.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1151-8. doi: 10.1016/j.ijrobp.2012.01.083. Epub 2012 Apr 18.

PMID:
22516806
2.

Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C, Kusunoki M.

Ann Surg Oncol. 2009 Dec;16(12):3488-98. doi: 10.1245/s10434-009-0617-z.

PMID:
19657699
3.

SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.

Tian YF, Chen TJ, Lin CY, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Shiue YL, Huang HY, Pan HY, Li CF, Chen SH.

Tumour Biol. 2013 Apr;34(2):1107-17. doi: 10.1007/s13277-013-0652-z. Epub 2013 Jan 18.

PMID:
23328995
4.

Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy.

Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Kawamura M, Okugawa Y, Okigami M, Hiro J, Uchida K, Mohri Y, Kusunoki M.

J Cancer Res Clin Oncol. 2013 Jan;139(1):131-8. doi: 10.1007/s00432-012-1308-x. Epub 2012 Sep 18.

PMID:
22986809
5.

Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.

Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, Lim SB, Kim JC.

Ann Surg Oncol. 2011 Nov;18(12):3271-7. doi: 10.1245/s10434-011-1740-1. Epub 2011 May 3.

PMID:
21537868
6.

Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.

Tural D, Ozturk M, Selcukbiricik F, Yildiz O, Elicin O, Turna H, Guney S, Ozguroglu M.

J BUON. 2013 Apr-Jun;18(2):385-90.

PMID:
23818350
7.

Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer.

Pucci S, Polidoro C, Joubert A, Mastrangeli F, Tolu B, Benassi M, Fiaschetti V, Greco L, Miceli R, Floris R, Novelli G, Orlandi A, Santoni R.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):381-388. doi: 10.1016/j.ijrobp.2016.10.018. Epub 2016 Oct 19.

PMID:
28068245
8.

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group.

Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.

PMID:
26189067
9.

GRP78 Protein Expression as Prognostic Values in Neoadjuvant Chemoradiotherapy and Laparoscopic Surgery for Locally Advanced Rectal Cancer.

Lee HY, Jung JH, Cho HM, Kim SH, Lee KM, Kim HJ, Lee JH, Shim BY.

Cancer Res Treat. 2015 Oct;47(4):804-12. doi: 10.4143/crt.2014.121. Epub 2015 Jan 30.

10.

Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.

Lin CY, Tian YF, Wu LC, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Wang YH, Shiue YL, Wu WR, Huang HY, Hsu HP, Li CF, Chen SH.

J Clin Pathol. 2012 Aug;65(8):687-92. doi: 10.1136/jclinpath-2012-200786. Epub 2012 May 8.

PMID:
22569540
11.

Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.

Arredondo J, Baixauli J, Beorlegui C, Arbea L, Rodríguez J, Sola JJ, Chopitea A, Hernández-Lizoáin JL.

Dis Colon Rectum. 2013 Apr;56(4):416-21. doi: 10.1097/DCR.0b013e318274d9c6.

PMID:
23478608
12.

Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.

Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS.

J Gastrointest Cancer. 2014 Mar;45(1):34-9. doi: 10.1007/s12029-013-9546-y.

13.

Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.

Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, Maretto I, Friso ML, Lonardi S, Mescoli C, Toppan P, Urso E, Nitti D.

Ann Surg Oncol. 2011 Sep;18(9):2461-8. doi: 10.1245/s10434-011-1638-y. Epub 2011 Mar 17.

PMID:
21416156
14.

Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Yu J, Li N, Wang X, Ren H, Wang W, Wang S, Song Y, Liu Y, Li Y, Zhou X, Luo A, Liu Z, Jin J.

Oncotarget. 2016 Sep 27;7(39):64233-64243. doi: 10.18632/oncotarget.11649.

15.

Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.

Madbouly KM, Hussein AM, Abdelzaher E.

Am J Surg. 2014 Sep;208(3):332-41. doi: 10.1016/j.amjsurg.2013.10.023. Epub 2014 Jan 17.

PMID:
24581995
16.

Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.

Schwaab J, Horisberger K, Ströbel P, Bohn B, Gencer D, Kähler G, Kienle P, Post S, Wenz F, Hofmann WK, Hofheinz RD, Erben P.

BMC Cancer. 2011 Aug 19;11:363. doi: 10.1186/1471-2407-11-363.

17.

Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.

Yasuda H, Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T, Kawamoto A, Inoue Y, Miki C, Kusunoki M.

Oncol Rep. 2009 Oct;22(4):709-17.

PMID:
19724847
18.

Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients.

Huang MY, Lin CH, Huang CM, Tsai HL, Huang CW, Yeh YS, Chai CY, Wang JY.

World J Surg. 2015 May;39(5):1257-67. doi: 10.1007/s00268-014-2917-0.

PMID:
25561186
19.

Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8+ Tumor-Infiltrating Lymphocytes Identified Patients With Poor Prognosis in Rectal Cancer: A Matched Comparison Analysis.

Lim YJ, Koh J, Kim S, Jeon SR, Chie EK, Kim K, Kang GH, Han SW, Kim TY, Jeong SY, Park KJ, Wu HG.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1216-1224. doi: 10.1016/j.ijrobp.2017.07.004.

PMID:
29165286
20.

Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies.

Belluco C, De Paoli A, Canzonieri V, Sigon R, Fornasarig M, Buonadonna A, Boz G, Innocente R, Perin T, Cossaro M, Polesel J, De Marchi F.

Ann Surg Oncol. 2011 Dec;18(13):3686-93. doi: 10.1245/s10434-011-1822-0. Epub 2011 Jun 21.

Supplemental Content

Support Center